Lantheus Holdings (LNTH)

Executive Summary

Lantheus Holdings is a commercial-stage biopharmaceutical company specializing in diagnostic imaging agents and radiopharmaceuticals, with a focus on cardiovascular and oncology applications. Its approved products include DEFINITY® for ultrasound imaging and PYLARIFY® for prostate cancer PET imaging. The company's strategy, "Find, Fight and Follow® disease," underpins its development of a pipeline with approximately 40 candidates across diagnostic imaging, radiopharmaceutical oncology, and cardiovascular disease. Lantheus benefits from a commercial infrastructure supporting its existing products while advancing clinical programs. Recent developments include the Phase 1/2 trial of LNTH2403 in osteosarcoma (recruiting) and ongoing studies for PYLARIFY in prostate cancer. With a market cap of ~$5.4B and a strong commercial base, Lantheus is well-positioned in the targeted radiopharmaceutical space, though pipeline execution remains key to growth.

Upcoming Catalysts (preview)

• Q3 2026PYLARIFY prostate cancer trial completion and potential label expansion75% success
• H2 2027LNTH2403 Phase 1/2 interim data readout in osteosarcoma50% success
• TBDPotential FDA approval or regulatory update for new imaging agent60% success